COVID‐associated non‐vasculitic thrombotic retiform purpura of the face and extremities: A case report

COVID‐associated non‐vasculitic thrombotic retiform purpura of the face and extremities: A case report

SARS‐CoV‐2 infection can manifest many rashes. However, thrombotic retiform purpura rarely occurs during COVID‐19 illness. Aggressive anti‐COVID‐19 therapy with a high‐dose steroid regimen led to rapid recovery. This immunothrombotic phenomenon likely represents a poor type 1 interferon response and...

Full description

Saved in:
Bibliographic Details
Published in:Clinical case reports Vol. 10; no. 12; pp. e6790 - n/a
Main Authors: Bunch, Connor M., Zackariya, Nuha, Thomas, Anthony V., Langford, Jack H., Aboukhaled, Michael, Thomas, Samuel J., Ansari, Aida, Patel, Shivani S., Buckner, Hallie, Miller, Joseph B., Annis, Christy L., Quate‐Operacz, Margaret A., Schmitz, Leslie A., Pulvirenti, Joseph J., Konopinski, Jonathan C., Kelley, Kathleen M., Hassna, Samer, Nelligan, Luke G., Walsh, Mark M.
Format: Journal Article
Language:English
Published: England John Wiley & Sons, Inc 01-12-2022
Wiley
Subjects:
acral lesions
Biopsy
Blood
Case reports
chilblains
Coronaviruses
COVID-19
Creatinine
Cytokines
Dehydrogenases
Emergency medical care
exanthema
Hypertension
Laboratories
Oxygen saturation
Proteins
Purpura
SARS‐CoV‐2
Severe acute respiratory syndrome coronavirus 2
Thrombosis
vasculitis
COVID‐19
exanthema
SARS‐CoV‐2
chilblains
vasculitis
acral lesions
purpura
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:SARS‐CoV‐2 infection can manifest many rashes. However, thrombotic retiform purpura rarely occurs during COVID‐19 illness. Aggressive anti‐COVID‐19 therapy with a high‐dose steroid regimen led to rapid recovery. This immunothrombotic phenomenon likely represents a poor type 1 interferon response and complement activation on the endothelial surface in response to acute infection. COVID‐associated rashes in adults usually associate with more severe COVID‐19 illness. For older, comorbid patients with mild to moderate COVID‐19 illness who develop a rash, administer early immunomodulating therapy to mitigate disease progression.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
content type line 23
ObjectType-Report-1
ISSN:2050-0904
2050-0904
DOI:10.1002/ccr3.6790